ETB, have been pharmacologically characterized and cloned (for review see 1) . The ETAreceptor appears to be the predominant vascular smooth muscle receptor, and selectively binds to ET-1 over  resulting in vasoconstriction.
The isopeptide nonselective ETB receptor is widely expressed (e.g. in liver and uterus) and is probably the predominant receptor in CNSand kidney, but its function is less well understood. It is known that the circulating blood levels of endothelins in patients are usually increased in a variety of cardiovascular, renal and inflammatory disease states. Several characteristics of ET-1-induced vasoconstriction are consistent with it being involved in the production of hypertension in man. An ETreceptor antagonist with appropriate affinity and selectivity may be useful in the treatment of hypertension, ischaemic or cyclosporin-induced renal damage, ulcerogenesis and cancer2~3). NOV. 1994 therefore developed. The screen was based on the measurement of binding of 125I-ET-1 to the human ETBreceptor, which was cloned and expressed in
Chinese hamster ovary cells (CHO-ETB) by our laboratories6D uring the screening of microbial fermentation extracts for their ability to inhibit the binding of 125I-ET-1 to the human ETB receptor, an extract of Fusarium aquaeductuum WC-5228, was found to be active. When subjected to an activity-guided fractionation, one active compound, 7-chloro-l -Omethylemodin, was isolated. This report describes the isolation and characterization of this compound, the preparation and testing of its analogs, and their inhibitory effects on ETBreceptor binding.
Results and Discussion
Binding of 125I-ET-1 to CHO-ETB cells was inhibited by ET-1 in a concentration-dependent fashion with an IC50 of 0.16nM (mean of 2 experiments which produced similar values). ET-2 and ET-3 also inhibited 12 5I-ET-1 binding with potencies similar to that of ET-1 (IC50 values=0.55nM and 0.35nM, respectively).
Thus, the binding site on CHO-ETBcells appears to be typical of the non-isopeptide selective ETBsubtype6~10). Binding was not inhibited by a number of unrelated peptides such as angiotensin II, bradykinin, and gpl20 (data not shown).
During the testing of a large number of natural products in a high-throughput screen for ETB binding inhibitors, an extract of fungal strain WC-5228 was found to inhibit 125I-ET-1 binding to CHO-ETB cells. Fungal strain WC-5228 was isolated from a moist dark brown loam soil sample collected in St. Louis, Missouri. Taxonomic studies on this strain was carried out from growth on PotatoDextrose Agar (PDA). Colonies on PDAare cream color to lightly yellow and slow growing reaching 4.5~5.0cm in diameter in two weeks at room temperature. The reverse pigment is absent and becoming dark yellow brown with age. The colony surface is wrinkled with aerial mycelium scarce to absent. Microconidia and chlamydospores are absent. Conidia are born directly from phialides arising from hyphae in groups resembling sporodochia. They are multi-septate (3~4 septa), crescent to strongly curved with potential lateral The compound responsible for the inhibitory activity, 7-chloro-l-O-methylemodin was isolated from the fungal extract using activity-guided fractionation ( Fig.  1 ). The IC50 for 7-chloro-l-Omethylemodin was 50fiu. Its non-chlorinated analog, 1-O-methylemodin, also isolated from the extract, but was not active at the maximum concentration of 7.0 mM.7-Chloro-l-O-methylemodin did not inhibit 125I-ET-1 binding to the ETA receptor expressed in A10 cells12) at 6.3mM.
Four chlorinated emodins (5-chloroemodin, 7-chloroemodin, 5,7-dichloroemodin, and 4,5,7-trichloroemodin) and two brominated emodins (7- bromoemodin and 5,7-dibromoemodin) were prepared from emodin. Their structures are shownin Table 1 shows the IC50 values of these compounds in the ETB receptor binding assay.
Monochlorinated, dichlorinated, and monobrominated emodins were active inhibitors of ETBbinding with potencies in the micromolar range (IC50: 1001 58 fiM). The 5,7-dibromoemodin was, however, much less active (IC5O=500/iM) and 4,5,7-tri- chloroemodin showed no activity.
Fig. 2. Structures of emodin derivatives.
Based on preliminary studies of structural requirements for activity, it appears that halogen substitution on the anthraquinone nucleus is essential for activity. Thus, the non-halogenated analog, 1-0-methylemodin, as well as emodin itself, were inactive. Of the six chlorinated and brominated derivatives prepared, most showed activity similar to 7-chloro-1 -O-methylemodin, although somewhat weaker. Dibromo and trichloro substitutions resulted in significantly diminished activity.
Several non-peptidic compounds possessing an- thraquinone ring system such as WS00913) have previously been reported as ETA-selective or ETA/ ETB-nonselective inhibitors.
To the best of our knowledge, the haloemodin type anthraqunones represent the first reported class of non-peptidic ETB-selective inhibitors, to clarify whether the haloemodin derivatives act as endothelin receptor antagonists further functional testing in a relevant assay will be necessary. The function of the ETA receptor in producing vasoconstriction is well established, but less well understood is the function of the ETBreceptor. Furthermore, the importance of the interaction between ETAand ETBreceptor stimulation in tissues containing both subtypes of receptor is also unclear. Having both ETA-and ETB-selective compounds as tools, it should now prove possible to more accurately define the functions of each of these receptor subtypes.
Experimental
Binding Assay The cloning of the humanETBreceptor and its expression in CHO cells has been previously described6).
The ETB receptor binding assay was carried out by culturing CHO-ETBcells in Hams F12 mediumsupplemented with 10%bovine calf serum, 300 /jg/ml geneticin (antibiotic G418) plus 2mML-glutamine in T-175 flasks. The cells from one con fluent flask were detached with trypsin and used to seed a 1,050-cm2 roller bottle. Medium was removed and replaced with 200 ml of fresh medium every 3 days, as well as 24 hours prior to use. Cells were used whencon fluency was reached. Onthe day of the assay, the CHO-ETB cells were removed from the roller bottle by scraping, collected by centrifugation, and resuspended in PBG (PBS supplemented with 0.1% glucose and 0.1% BSA subtracted from the total binding to yield specific binding. The ETAreceptor binding was carried out with rat aortic smooth muscle A10 cells, which expressed the rat ETAreceptor, using modifications of a previously described procedure12).
Fermentation
The producing organism used in this study was F. aquaeductuum WC-5228. Frozen vegetative preparations were maintained in 10% glycerol -5% sucrose solution stored at -80°C for use as working stocks. A seed culture of F. aquaeductuum WC-5228 was prepared by transferring 4ml of the frozen vegetative stock into a 500-ml Erlenmeyer flask containing 100 ml of the seed medium (4% glucose, 0.5% yeast extract, 0.0001% FeSO4, 0.05% MgSO4, 0.05% KC1, 0.1% KH2PO4 and0.3% NaNO3). This seed culture was incubated at 28°C on a rotary shaker (250 rpm). After 72 hours, 4-ml aliquots were transferred to 500-ml Erlenmeyer flasks containing 100 ml of production medium (8% potato flakes and 2% glucose). The production cultures were incubated for 6 days at 28°C on a rotary shaker (250 rpm).
Isolation and Characterization of 7-Chloro-l-Omethylemodin
The isolation of 7-chloro-l-O-methylemodin was monitored by the ETBreceptor'binding assay, and the procedure is illustrated in Fig. 1 . Briefly, the fermentation broth of F. aquaeductuum WC-5228 was extracted with ethyl acetate. The extract was dissolved in aqueous methanol and partitioned against pre-equilibrated hexane, carbon tetrachloride, and chloroform sequentially. The chloroform extract was purified by Sephadex LH-20 column chromatography. The bioactive fractions were collected, concentrated and crystallized in alcohol to give brown needles (5.0mg). The compound has the following physico-chemical pro- Preparation of Haloemodin Derivatives Chlorinated emodins were prepared from emodin (Aldrich) . Briefly, emodin dissolved in a mixture of CHCl3-MeOH (10: 1) was added to an ice-chilled solution of CHCI3 containing an equal molar amount of chlorine. After stirring 6 hours at room temperature, the reaction mixture was concentrated in vacuo to give a red oil. The oil was purified by flash column chromatography of silica gel with a solvent mixture of CH2C12 -MeOH-H2O(100 : 2 : 0.1 to 100:5:0.5). 5-Chloroemodin was first and 7-Chloroemodin then eluted as major products, followed by 5,7-dichloroemodin. The three products were crystallized in alcohol as brown powders. 5-Chloroemodin, *H NMR (DMSO-d6) S: 2.42 (CH3), 6.78 (7-H) 
